Today: The Aquinox Pharmaceuticals Inc. (AQXP) Coverage Initiated by Analysts at Leerink Swann

The Aquinox Pharmaceuticals Inc. (AQXP) Coverage Initiated by Analysts at Leerink Swann

Leerink Swann began coverage on shares of Aquinox Pharmaceuticals Inc. (NASDAQ:AQXP) in a research report released on Tuesday. The brokerage issued an outperform rating and a $24.00 target price on the stock.

A number of other research firms also recently commented on AQXP. Jefferies Group lifted their price target on Aquinox Pharmaceuticals from $7.00 to $9.00 and gave the stock a hold rating in a research note on Friday, August 5th. Canaccord Genuity set a $22.00 price target on Aquinox Pharmaceuticals and gave the stock a buy rating in a research note on Thursday, July 21st. Finally, Zacks Investment Research downgraded Aquinox Pharmaceuticals from a hold rating to a sell rating in a research note on Tuesday, August 9th. Two investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. Aquinox Pharmaceuticals currently has a consensus rating of Buy and an average target price of $20.29.

Aquinox Pharmaceuticals (NASDAQ:AQXP) remained flat at $14.22 during trading on Tuesday. 26,013 shares of the company were exchanged. The company’s 50-day moving average price is $12.06 and its 200-day moving average price is $9.07. Aquinox Pharmaceuticals has a 52-week low of $6.01 and a 52-week high of $16.75. The firm’s market cap is $244.75 million.

Aquinox Pharmaceuticals (NASDAQ:AQXP) last posted its quarterly earnings results on Thursday, August 4th. The company reported ($0.63) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.41) by $0.22. On average, equities research analysts expect that Aquinox Pharmaceuticals will post ($2.23) earnings per share for the current fiscal year.

In other Aquinox Pharmaceuticals news, major shareholder Bros. Advisors Lp Baker acquired 2,783,605 shares of Aquinox Pharmaceuticals stock in a transaction dated Tuesday, September 20th. The stock was acquired at an average cost of $12.25 per share, for a total transaction of $34,099,161.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Insiders own 3.00% of the company’s stock.

Several institutional investors have recently modified their holdings of AQXP. Vanguard Group Inc. increased its position in shares of Aquinox Pharmaceuticals by 2.0% in the second quarter. Vanguard Group Inc. now owns 110,529 shares of the company’s stock valued at $731,000 after buying an additional 2,197 shares in the last quarter. BlackRock Fund Advisors increased its position in shares of Aquinox Pharmaceuticals by 1.8% in the second quarter. BlackRock Fund Advisors now owns 228,693 shares of the company’s stock valued at $1,514,000 after buying an additional 3,977 shares in the last quarter. BlackRock Advisors LLC increased its position in shares of Aquinox Pharmaceuticals by 2.1% in the second quarter. BlackRock Advisors LLC now owns 404,575 shares of the company’s stock valued at $2,678,000 after buying an additional 8,280 shares in the last quarter. BlackRock Inc. increased its position in shares of Aquinox Pharmaceuticals by 24.3% in the first quarter. BlackRock Inc. now owns 50,600 shares of the company’s stock valued at $446,000 after buying an additional 9,900 shares in the last quarter. Finally, Geode Capital Management LLC increased its position in shares of Aquinox Pharmaceuticals by 21.8% in the first quarter. Geode Capital Management LLC now owns 62,949 shares of the company’s stock valued at $555,000 after buying an additional 11,268 shares in the last quarter. Institutional investors and hedge funds own 68.20% of the company’s stock.

Aquinox Pharmaceuticals Company Profile

Related posts

Leave a Comment